![Daniel J. Wattier](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Daniel J. Wattier
Vorstandsvorsitzender bei Valocor Therapeutics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Geoffrey W. Hoffmann | M | - |
Network Immunology, Inc.
![]() Network Immunology, Inc. Miscellaneous Commercial ServicesCommercial Services Network Immunology, Inc. developing novel immuno-therapies based on immune network theory services. It is a preclinical stage biotechnology company, which focuses on discovering and developing novel treatments for autoimmune conditions and infectious diseases. The company was founded by George Hoffmann and Geoffrey W. Hoffmann in 2003 and is headquartered in Vancouver, Canada. | 21 Jahre |
George Hoffmann | M | - |
Network Immunology, Inc.
![]() Network Immunology, Inc. Miscellaneous Commercial ServicesCommercial Services Network Immunology, Inc. developing novel immuno-therapies based on immune network theory services. It is a preclinical stage biotechnology company, which focuses on discovering and developing novel treatments for autoimmune conditions and infectious diseases. The company was founded by George Hoffmann and Geoffrey W. Hoffmann in 2003 and is headquartered in Vancouver, Canada. | 21 Jahre |
Jean-Pierre Julien | M | - |
ImStar Therapeutics, Inc.
![]() ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | 12 Jahre |
Julia G. Levy | M | 89 |
Valocor Therapeutics, Inc.
![]() Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist.
ImStar Therapeutics, Inc.
![]() ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | - |
David Hunt | M | - |
Valocor Therapeutics, Inc.
![]() Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | - |
Agnes Chan | M | - |
Valocor Therapeutics, Inc.
![]() Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | - |
Pat R. Brady | M | - |
Valocor Therapeutics, Inc.
![]() Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | - |
Ian John Massey | M | 73 |
ImStar Therapeutics, Inc.
![]() ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | - |
Jeffrey Charpentier | M | - |
ImStar Therapeutics, Inc.
![]() ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | 8 Jahre |
H. Christian Fibiger | M | 80 |
ImStar Therapeutics, Inc.
![]() ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | - |
John V. Hatton | M | - |
Network Immunology, Inc.
![]() Network Immunology, Inc. Miscellaneous Commercial ServicesCommercial Services Network Immunology, Inc. developing novel immuno-therapies based on immune network theory services. It is a preclinical stage biotechnology company, which focuses on discovering and developing novel treatments for autoimmune conditions and infectious diseases. The company was founded by George Hoffmann and Geoffrey W. Hoffmann in 2003 and is headquartered in Vancouver, Canada. | - |
Jonathan Willmer | M | - |
Network Immunology, Inc.
![]() Network Immunology, Inc. Miscellaneous Commercial ServicesCommercial Services Network Immunology, Inc. developing novel immuno-therapies based on immune network theory services. It is a preclinical stage biotechnology company, which focuses on discovering and developing novel treatments for autoimmune conditions and infectious diseases. The company was founded by George Hoffmann and Geoffrey W. Hoffmann in 2003 and is headquartered in Vancouver, Canada. | - |
Edwin Gershom | M | - |
Network Immunology, Inc.
![]() Network Immunology, Inc. Miscellaneous Commercial ServicesCommercial Services Network Immunology, Inc. developing novel immuno-therapies based on immune network theory services. It is a preclinical stage biotechnology company, which focuses on discovering and developing novel treatments for autoimmune conditions and infectious diseases. The company was founded by George Hoffmann and Geoffrey W. Hoffmann in 2003 and is headquartered in Vancouver, Canada. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jennifer Kaufman-Shaw | M | 74 |
ImStar Therapeutics, Inc.
![]() ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Kanada | 14 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Daniel J. Wattier
- Persönliches Netzwerk